Heike Otto

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Top Venues

Clinical and translational science

Expert opinion on drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Till A Röhn, Shin Numao, Heike Otto, Christian Loesche, Gebhard Thoma
Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors. Expert opinion on drug discovery 16 (12) (2021)